Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 2/20 | 0.44 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.33 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.33 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.32 |
| ▸ | HPGD | P15428 | 5/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21379597 | 0.82 | HSD17B3 (0.46) | HSD17B3ALDH2BRD4SMN1; SMN2ALDH1A2 | |
| SCHEMBL1147722 | 0.79 | HSD17B3 (0.51) | HSD17B3SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL2454830 | 0.78 | ALDH1A1 (0.50) | HSD17B3BRD4SMN1; SMN2MAOBALDH1A1 | |
| SCHEMBL25190307 | 0.77 | HSD17B3 (0.42) | HSD17B3ALDH2BRD4SMN1; SMN2ALDH1A2 | |
| SCHEMBL4058366 | 0.76 | RXFP1 (0.47) | HSD17B3BRD4SMN1; SMN2MAOBALDH1A1 | |
| SCHEMBL20957619 | 0.71 | HSD17B3 (0.58) | HSD17B3SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL6081605 | 0.70 | HSD17B3 (0.43) | HSD17B3SMN1; SMN2MAOBALDH1A1KDM4E | |
| SCHEMBL5483956 | 0.68 | MAOB (0.56) | BRD4MAOBALDH1A1KDM4EMAPT | |
| SCHEMBL59843 | 0.68 | HSD17B3 (0.33) | HSD17B3SMN1; SMN2POLBKMT2AMAPK1 | |
| SCHEMBL9054643 | 0.68 | HSD17B3 (0.67) | HSD17B3SMN1; SMN2MAOBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0018112-B1 | SUBSTRATES AND METHOD FOR DETERMINING PROTEOLYTIC ENZYMES | Smith, Robert Eugene (US) | 1983-07-20 | — | — | EP | claimed |
| WO-2024042107-A1 | COMPOSITION | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042106-A1 | COMPOSITION | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| US-20240002688-A1 | COMPOSITION | MERCK PATENT GMBH (DE) | 2024-01-04 | — | — | US | disclosed |
| US-20230320140-A1 | DEVICE | MERCK PATENT GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| EP-4232518-A2 | COMPOSITION | Merck Patent GmbH (DE) | 2023-08-30 | — | — | EP | disclosed |
| EP-4208904-A1 | DEVICE | Merck Patent GmbH (DE) | 2023-07-12 | — | — | EP | disclosed |
| US-20230107892-A1 | NEGATIVE TYPE PHOTOSENSITIVE COMPOSITION COMPRISING REFLECTANCE MODIFIER | MERCK PERFORMANCE MATERIALS GERMANY GMBH (DE) | 2023-04-06 | — | — | US | disclosed |
| US-11579527-B2 | Negative type photosensitive composition comprising black colorant | MERCK PATENT GMBH (DE) | 2023-02-14 | — | — | US | disclosed |
| US-11579530-B2 | Negative type photosensitive composition | MERCK PATENT GMBH (DE) | 2023-02-14 | — | — | US | disclosed |
| US-7812042-B2 | Pharmaceutical compositions and therapeutic applications for the use of a novel vitamin B12 derivative, N-acetyl-L-cysteinylcobalamin | KENT STATE UNIVERSITY (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2187892-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | Bioneris AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009038533-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | BIONERIS AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| US-20080113900-A1 | Pharmaceutical compositions and therapeutic applications for the use of a synthetic vitamin B12 derivative, glutathionylcobalamin | KENT STATE UNIVERSITY | 2008-05-15 | — | — | US | disclosed |
| US-20080076733-A1 | Pharmaceutical compositions and therapeutic applications for the use of a novel vitamin B12 derivative, N-acetyl-L-cysteinylcobalamin | KENT STATE UNIVERSITY | 2008-03-27 | — | — | US | disclosed |
| WO-2003055890-A1 | THIENOPYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003055489-A1 | 2,4-DIAMINO-PYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003055866-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | disclosed |
| EP-0018112-B1 | SUBSTRATES AND METHOD FOR DETERMINING PROTEOLYTIC ENZYMES | Smith, Robert Eugene (US) | 1983-07-20 | — | — | EP | disclosed |
| EP-0018112-A1 | Substrates and method for determining proteolytic enzymes | Smith, Robert Eugene (US) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113900-A1 | Pharmaceutical compositions and therapeutic applications for the use of a synthetic vitamin B12 derivative, glutathionylcobalamin | CBS, CTH, BHMT2 | HSD17B3 1828/4885ALDH2 995/4885BRD4 2844/4885 |
| US-20080076733-A1 | Pharmaceutical compositions and therapeutic applications for the use of a novel vitamin B12 derivative, N-acetyl-L-cysteinylcobalamin | CBS, MMAB, AHCY | HSD17B3 3359/4885ALDH2 771/4885BRD4 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.